Risuteganib shows potential in dry AMD

SAN FRANCISCO — Risuteganib showed potential for the treatment of intermediate dry age-related macular degeneration, according to study results presented at Retina Subspecialty Day prior to the American Academy of Ophthalmology annual meeting.“The path…